

John J Powers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9000370/publications.pdf>

Version: 2024-02-01

86
papers

1,187
citations

471061

17
h-index

395343

33
g-index

88
all docs

88
docs citations

88
times ranked

1852
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF- β -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. <i>Immunity</i> , 2022, 55, 115-128.e9.	6.6	62
2	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. <i>Cancer Research</i> , 2022, 82, 859-871.	0.4	21
3	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T α cells. <i>Cancer Cell</i> , 2022, 40, 545-557.e13.	7.7	53
4	Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1184-1194.	1.9	12
5	Exposure to a mycovirus containing <i>Aspergillus Flavus</i> reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controls. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100279.	0.7	5
6	HDAC11 regulates expression of C/EBP β and immunosuppressive molecules in myeloid-derived suppressor cells. <i>Journal of Leukocyte Biology</i> , 2021, 109, 891-900.	1.5	7
7	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. <i>Blood Advances</i> , 2021, 5, 2740-2750.	2.5	6
8	Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. <i>JCI Insight</i> , 2021, 6, .	2.3	8
9	Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing <i>Aspergillus flavus</i> . <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 350-358.	0.3	4
10	HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the E μ 4-TCL1 Model. <i>Frontiers in Immunology</i> , 2020, 11, 590072.	2.2	14
11	The dual PI3K β /CK1 β inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. <i>Blood Advances</i> , 2020, 4, 3072-3084.	2.5	52
12	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. <i>Blood</i> , 2020, 135, 191-207.	0.6	40
13	Indian Buddhist concepts of normative and deviant bodies: can ancient sexual mores be reconciled with modern sensibilities?. <i>Religion</i> , 2019, 49, 735-744.	0.3	2
14	Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 474-474.	0.6	1
15	Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3382-3382.	0.6	1
16	Abstract 4723: Combinatorial efficacy of anti-PD1 treatment and selective histone deacetylase 6 (HDAC6) inhibition in chronic lymphocytic leukemia (CLL). , 2019, , .		0
17	Abstract LB-074: Priming the tumor microenvironment with epigenetic modifiers to overcome resistance to immune checkpoint inhibitors. , 2019, , .		0
18	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 1434-1444.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2018, 2, 3012-3024.	2.5	16
20	A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. <i>Leukemia Research</i> , 2018, 74, 89-96.	0.4	42
21	Abstract 1703: The HDAC6 inhibitor Nexturastat A improves in vivo PD-1 immune blockade. , 2018, , .		0
22	Abstract 4967: HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition. , 2018, , .		0
23	Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment. <i>Blood</i> , 2018, 132, 1105-1105.	0.6	1
24	Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival. <i>Blood</i> , 2018, 132, 3223-3223.	0.6	1
25	T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. <i>Blood</i> , 2017, 130, 146-155.	0.6	54
26	Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. <i>Journal of Leukocyte Biology</i> , 2017, 102, 475-486.	1.5	44
27	HDAC11 as a candidate therapeutic target in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8029-8029.	0.8	1
28	Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6. , 2017, , .		0
29	Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. <i>Methods in Molecular Biology</i> , 2016, 1436, 129-145.	0.4	7
30	Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2016, 47, 78-83.	0.4	17
31	Functional Analysis of Histone Deacetylase 11 (HDAC11). <i>Methods in Molecular Biology</i> , 2016, 1436, 147-165.	0.4	8
32	Essential role of HDAC6 in the regulation of PD-L1 in melanoma. <i>Molecular Oncology</i> , 2016, 10, 735-750.	2.1	125
33	Abstract 545: Differential regulation of human T-cells by TGR-1202, a novel PI3K δ inhibitor. , 2016, , .		9
34	A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease. <i>Blood</i> , 2016, 128, 1892-1892.	0.6	4
35	Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202. <i>Blood</i> , 2016, 128, 3236-3236.	0.6	3
36	Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 4485: Regulation of chronic lymphocytic leukemia (CLL) immunobiology by histone deacetylase 6 (HDAC6). , 2016, , .		0
38	Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model. Blood, 2016, 128, 2035-2035.	0.6	0
39	Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology, 2015, 9, 1447-1457.	2.1	111
40	<scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides. American Journal of Hematology, 2015, 90, 602-607.	2.0	50
41	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology, 2015, 63, 579-585.	1.0	98
42	Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP- β , in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition. Blood, 2014, 124, 225-225.	0.6	1
43	Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 3311-3311.	0.6	11
44	Abstract 5537: Histone deacetylase 11 (HDAC11) regulates B cell lymphopoiesis and potentiates plasma cell survival in multiple myeloma. , 2014, , .		0
45	Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy. , 2014, , .		0
46	A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma. Blood, 2014, 124, 4715-4715.	0.6	0
47	Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition. Blood, 2014, 124, 5423-5423.	0.6	0
48	A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentiation and Survival. Blood, 2013, 122, 1907-1907.	0.6	1
49	A Novel Role For Histone Deacetylase 11 (HDAC11) As a Regulator Of Neutrophil Function and Differentiation In Normal and Malignant Hematopoiesis. Blood, 2013, 122, 2267-2267.	0.6	1
50	Abstract 692: Histone deacetylase 11 is an epigenetic regulator of CD8+ T-cell effector function and memory formation.. , 2013, , .		0
51	Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP- β . Blood, 2013, 122, 4887-4887.	0.6	0
52	Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood, 2012, 120, 1027-1038.	0.6	60
53	Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL). Blood, 2012, 120, 1660-1660.	0.6	5
54	Abstract 3555: Histone deacetylase 6 as a novel regulator of the immunogenicity and aggressiveness of melanoma. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 3554: The histone deacetylase inhibitor LBH589 augments anti-tumor immunity through direct effects on tumor and immune cells leading to impaired tumor progression <i>in vivo</i> . , 2012, , .		0
56	Abstract 4260: Histone deacetylase 11 (HDAC11) as a novel therapeutic target in the regulation of myeloid-derived suppressor cell (MDSC). , 2012, , .		0
57	Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis. <i>Blood</i> , 2012, 120, 4728-4728.	0.6	0
58	Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine. <i>Blood</i> , 2012, 120, 3828-3828.	0.6	0
59	Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). <i>Blood</i> , 2012, 120, 829-829.	0.6	0
60	Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype. <i>Blood</i> , 2012, 120, 840-840.	0.6	0
61	Gender and Virtue in Indian Buddhism. <i>CrossCurrents</i> , 2011, 61, 428-440.	0.0	1
62	A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2011, 52, 668-679.	0.6	33
63	Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2â€™-deoxycytidine. <i>Leukemia Research</i> , 2011, 35, 1193-1199.	0.4	15
64	Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. <i>Leukemia Research</i> , 2011, 35, 394-404.	0.4	17
65	The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 1363-1363.	0.6	1
66	Epigenetic Modulation of STAT3 by Histone Deacetylase 6 (HDAC6) Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). <i>Blood</i> , 2011, 118, 519-519.	0.6	2
67	Abstract 5526: Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2â€™-deoxycytidine. , 2011, , .		0
68	Tubastatin A, a Selective HDAC6 Inhibitor, Enhances Antigen-Presenting Cell (APC) Function and Restores the Responsiveness of Anergic CD4+ T Cells. <i>Blood</i> , 2011, 118, 520-520.	0.6	0
69	Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2011, 118, 1725-1725.	0.6	1
70	A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion. <i>Blood</i> , 2011, 118, 2439-2439.	0.6	1
71	Circumventing Immune Tolerance Through Epigenetic Modification. <i>Current Pharmaceutical Design</i> , 2010, 16, 268-276.	0.9	11
72	Abstract 4771: Molecular, epigenetic, and phenotypic repolarization of human T lymphocytes using 5-aza-2â€™-deoxycytidine increases CD8 responsiveness and induces Th1 polarity. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
73	Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL. <i>Blood</i> , 2010, 116, 4630-4630.	0.6	0
74	A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2010, 116, 2925-2925.	0.6	1
75	Molecular, Epigenetic, and Phenotypic Repolarization of T Lymphocytes From Chronic Lymphocytic Leukemia Patients Using 5-Aza-2-Deoxycytidine. <i>Blood</i> , 2010, 116, 4651-4651.	0.6	0
76	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen. <i>Clinical Cancer Research</i> , 2009, 15, 3406-3415.	3.2	38
77	Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.. <i>Blood</i> , 2009, 114, 2376-2376.	0.6	3
78	Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009, 114, 4413-4413.	0.6	0
79	Molecular Profiling of Cancer Testis Antigens in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 4701-4701.	0.6	0
80	Restoring the Functional Immunogenicity of Chronic Lymphocytic Leukemia Using Epigenetic Modifiers.. <i>Blood</i> , 2009, 114, 5116-5116.	0.6	0
81	Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy.. <i>Blood</i> , 2009, 114, 2204-2204.	0.6	0
82	A Comprehensive Lymphocyte Analysis of Dasatinib Treated Chronic Myelogenous Leukemia Patients Reveals T-Cell Oligoclonality.. <i>Blood</i> , 2008, 112, 1114-1114.	0.6	2
83	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, An Immunogenic Cancer Testis Antigen. <i>Blood</i> , 2008, 112, 4207-4207.	0.6	0
84	Changes in Immunogenicity of Chronic Lymphocytic Leukemia Cells Mediated by Epigenetic Modifiers. <i>Blood</i> , 2008, 112, 4202-4202.	0.6	28
85	The novel differentiation of human blood mononuclear cells into CD1a-negative dendritic cells is stimulated in the absence of exogenous cytokines by an extract prepared from pinecones. <i>International Immunopharmacology</i> , 2003, 3, 209-223.	1.7	10
86	Mothering: Moral Cultivation in Buddhist and Feminist Ethics. <i>Philosophy East and West</i> , 1994, 44, 1.	0.0	3